Physician profile
John L Antus
NPI 1740241314
$3,893.22
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,207 · 2020: $1,206 · 2021: $853 · 2022: $612 · 2023: $15.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $560.94 | 2019-2023 | Ozempic, Rybelsus |
| Amgen INC. | $469.88 | 2019-2022 | |
| Pfizer INC. | $458.76 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $383.80 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $301.68 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $289.10 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $172.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $135.66 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $117.17 | 2019-2022 | |
| Lilly USA, LLC | $92.11 | 2019-2021 | |
| Eisai INC. | $91.11 | 2020-2021 | |
| Astellas Pharma US INC | $88.11 | 2019-2021 | |
| Amarin Pharma, INC. | $79.71 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.15 | 2022 | |
| Glaxosmithkline, LLC. | $71.98 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $65.74 | 2019 | |
| Abbvie INC. | $47.50 | 2021-2022 | |
| Allergan, INC. | $43.63 | 2019 | |
| Mylan Specialty L.P. | $38.14 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $28.54 | 2022 | |
| Medtronic, INC. | $25.16 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.25 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $21.04 | 2022 | |
| Antares Pharma, INC. | $19.21 | 2020 | |
| Mdd US Operations, LLC | $18.85 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.53 | 2020 | |
| Collegium Pharmaceutical, INC. | $18.14 | 2019 | |
| Abbott Laboratories | $17.25 | 2021 | |
| Avanir Pharmaceuticals, INC. | $17.19 | 2019 | |
| Esperion Therapeutics, INC. | $15.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.94 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.56 | 2020 | |
| Biogen, INC. | $14.42 | 2021 | |
| Scilex Pharmaceuticals INC. | $14.25 | 2019 | |
| Cmp Pharma, INC. | $12.24 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Antus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.